New drug TRX-100 takes first step: safety check in healthy people
NCT ID NCT07526506
First seen Jun 24, 2026 · Last updated Aug 04, 2026 · Updated 3 times
Summary
This Phase 1 trial is testing the safety of a new drug called TRX-100 in 24 healthy adults aged 18 to 65. Participants will receive either TRX-100 or a placebo, and researchers will monitor side effects and how the drug moves through the body. This is an early-stage study with no direct treatment benefit, designed to gather essential safety data before testing in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TRX-100
- What could go wrong
- This is a very early Phase 1 study in only 24 healthy people, so it cannot show whether TRX-100 works for any disease. Side effects are possible and will be closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Scientia Clinical Research Ltd.
RECRUITINGRandwick, New South Wales, 2031, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?